Company: DAWN
Filing Date: 2025-04-11
Form Type: DEF 14A
Source: 0001140361-25-013462
Chunk: 62

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-04-11
Form: DEF 14A
Chunk 62
---
19,761,110 |     |       22,201,175 |     |    5,427,365 |     |    7,770,283 |     |                          65 |     | 100 |     |   -72,754,000 |

| (1) | Jeremy Benderserved as the Company’s Principal Executive (our “PEO”) for the entirety of fiscal years 2021, 2022, 2023, and 2024. The Company’s other non-PEO NEOs for the indicated fiscal years were as follows: |

| − | 2024: Charles York, II, Samuel Blackman, and Adam Dubow |

| − | 2023: Charles York, II, Samuel Blackman, and Adam Dubow |

| − | 2021 and 2022: Charles York, II and Samuel Blackman |

| (2) | Amounts reported in these columns represent (i) the total compensation reported in the Summary Compensation Table for the indicated fiscal year in the case of our PEO and (ii) the average of the total compensation reported in the Summary Compensation Table for the non-PEO NEOs in the indicated year for such years. |

| (3) | Amounts reported in these columns represent the compensation actually paid to our PEO for the indicated fiscal year, as calculated under Item 402(v) of Regulation S-K based on his total compensation reported in the Summary Compensation Table for the indicated fiscal years and adjusted as shown in the tables below: |

|     |     |                                                                                                                                                                                      |     |       2021 
        ($) |     |       2022 
        ($) |     |       2023 
        ($) |     |      2024 
       ($) |
|     |     | Summary Compensation Table - Total Compensation(a)                                                                                                                                   |     | 19,761,110 |     |  5,086,456 |     |  6,913,959 |     | 6,560,577 |
| -   |     | Grant Date Fair Value of Stock Awards and Option Awards Granted in Fiscal Year(b)                                                                                                    |     | 18,924,289 |     |  4,174,256 |     |  5,865,559 |     | 5,364,977 |
| +   |     | Fair Value at Fiscal Year End of Outstanding and Unvested Stock Awards and Option Awards Granted in Fiscal Year(c)                                                                   |